BTIG Analyst Raises Price Target for Spyre Therapeutics (NASDAQ:SYRE) to $112 Amid Positive Clinical Trial Results
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameCofina SGPS SA
-
Registration countryPortugal
-
IndustryMedia
-
М/S&P/F
*** /*** /***









